Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer, January 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 282 articles: HTML format

Single Articles

1. YANG CY, Ho SC, Chiu YW, Weng YH, et al
   Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
   J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
   PubMed    
   Abstract available
   
   

2. YAMAMOTO H, Oura S
   Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
   Cureus. 2025;17:e98260.
   PubMed    
   Abstract available
   
   

3. SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
   Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
   Mol Cancer Res. 2026;24:84.
   PubMed    
   
   
   

4. ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
   Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
   Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
   PubMed    
   Abstract available
   
   

5. SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
   Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
   Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
   PubMed    
   Abstract available
   
   

6. LEE J, Jung H, Kim EG, Ahn J, et al
   Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
   Sci Adv. 2026;12:eady0041.
   PubMed    
   Abstract available
   
   

7. JURCZOK N, Dernbach G, Ebner B, Plage H, et al
   Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
   Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
   PubMed    
   Abstract available
   
   

8. BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
   Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
   South Asian J Cancer. 2025;14:810-814.
   PubMed    
   Abstract available
   
   

9. SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
   DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
   Vet Sci. 2025;12:1209.
   PubMed    
   Abstract available
   
   

10. WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
    Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
    Molecules. 2025;30:4802.
    PubMed    
    Abstract available
    
    

11. KAYER A, Ozen A, Dinleyici EC
    Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
    Medicina (Kaunas). 2025;61:2240.
    PubMed    
    Abstract available
    
    

12. SONG B, Lee H, Lee S, Hong SK, et al
    Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
    Investig Clin Urol. 2026;67:24-31.
    PubMed    
    Abstract available
    
    

13. CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
    Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
    Asian J Urol. 2025;12:471-477.
    PubMed    
    Abstract available
    
    

14. ANIS O, Bar V, Zundelevich A, Anil SM, et al
    Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
    Asian J Urol. 2025;12:534-543.
    PubMed    
    Abstract available
    
    

15. LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
    Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
    Asian J Urol. 2025;12:520-528.
    PubMed    
    Abstract available
    
    

16. SONG M, Ren H, Wang L, Zhou Y, et al
    Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
    Bioengineering (Basel). 2025;12:1338.
    PubMed    
    Abstract available
    
    

17. CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
    The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:4017.
    PubMed    
    Abstract available
    
    

18. PLAGE H, Biernath N, Furlano K, Weinberger S, et al
    Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
    Cancers (Basel). 2025;17:3990.
    PubMed    
    Abstract available
    
    

19. HOSHI S, Meguro S, Makabe S, Onagi A, et al
    Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:3964.
    PubMed    
    Abstract available
    
    

20. XIAO B, Zeng Q, Peng X, He Q, et al
    An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
    BMC Med Imaging. 2025;25:513.
    PubMed    
    Abstract available
    
    

21. LI C, Meng F, Lu C, Li A, et al
    A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
    J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
    PubMed    
    Abstract available
    
    

22. YANG CW, Yen CH, Chien TM, Yu SY, et al
    Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
    Mol Biol Rep. 2025;53:234.
    PubMed    
    Abstract available
    
    

23. LI L, Ren F, Liu Z, Tian X, et al
    Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
    Front Immunol. 2025;16:1668356.
    PubMed    
    Abstract available
    
    

24. HO PARK J, Lee H, Lee S, Hong SK, et al
    Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
    Front Oncol. 2025;15:1680595.
    PubMed    
    Abstract available
    
    

25. KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
    Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
    IJU Case Rep. 2025;9:e70119.
    PubMed    
    Abstract available
    
    

26. PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
    The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
    Curr Urol Rep. 2025;27:3.
    PubMed    
    Abstract available
    
    

27. XU M, Yue S, Chen Z, Li R, et al
    hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
    Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
    PubMed    
    
    
    

28. WANG Y, Xue H, Xu S, Qin Y, et al
    Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
    Afr J Reprod Health. 2025;29:204-216.
    PubMed    
    Abstract available
    
    

29. AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
    Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
    BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
    PubMed    
    
    
    

30. MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
    Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
    BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
    PubMed    
    
    
    

31. ZHONG MY, Zou XC, Chen PH
    Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
    Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
    PubMed    
    Abstract available
    
    

32. ZHANG M, Chen C, Zeng X, Zhao Q, et al
    Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
    Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
    PubMed    
    Abstract available
    
    

33. TAN J, Wang Y, Huang J, Dong B, et al
    Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
    Am J Mens Health. 2025;19:15579883251404985.
    PubMed    
    Abstract available
    
    

34. HU Z, Zeng D, Zhao X, Luo Y, et al
    Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
    Cancer Control. 2025;32:10732748251411011.
    PubMed    
    Abstract available
    
    

35. HUANG J, Chen D, Ji G, Ma J, et al
    ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
    J Transl Med. 2025;23:1427.
    PubMed    
    Abstract available
    
    

36. NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
    Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
    Clin Genitourin Cancer. 2025;24:102477.
    PubMed    
    Abstract available
    
    

37. OLUMOYIN K, El Naqa L, Rejniak K
    Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
    ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
    PubMed    
    Abstract available
    
    

38. HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
    Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
    Bladder Cancer. 2025;11:23523735251409720.
    PubMed    
    Abstract available
    
    

39. XUE Z, Qie Y, Shen C, Wu Z, et al
    Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
    PubMed    
    Abstract available
    
    

40. LV J, Li K, Zhou J, Yu R, et al
    Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
    J Exp Clin Cancer Res. 2025;44:324.
    PubMed    
    Abstract available
    
    

41. ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
    Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
    World J Urol. 2025;44:65.
    PubMed    
    Abstract available
    
    

42. LIU S, Liu T, Yang C, Mou Z, et al
    Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
    Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
    PubMed    
    Abstract available
    
    

43. LIU H, Jiang X, Wang T, Zhang G, et al
    Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
    Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
    PubMed    
    Abstract available
    
    

44. PEKER P
    Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
    World J Urol. 2025;44:64.
    PubMed    
    
    
    

45. VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
    Proteomes. 2025;13:65.
    PubMed    
    Abstract available
    
    

46. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
    PubMed    
    Abstract available
    
    

47. CARROLL TF, Bardot JP, David J, Zucker M, et al
    Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
    PubMed    
    Abstract available
    
    

48. OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
    Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
    Curr Oncol. 2025;32:699.
    PubMed    
    Abstract available
    
    

49. HU K, Ma X, Luo L, Li P, et al
    FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
    J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
    PubMed    
    Abstract available
    
    

50. MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
    Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Open Sci. 2025;83:54-63.
    PubMed    
    Abstract available
    
    

51. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Bladder Cancer Burden in the USA: Population Scenarios for 2040.
    Eur Urol Open Sci. 2025;83:99-108.
    PubMed    
    Abstract available
    
    

52. ZHUANG J, Yu H, Cao Q, Bai R, et al
    Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
    Eur Urol Open Sci. 2025;83:36-45.
    PubMed    
    Abstract available
    
    

53. XIANG J, Luo Y, Zhang B, Ke K, et al
    Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
    Front Oncol. 2025;15:1670574.
    PubMed    
    Abstract available
    
    

54. ZHANG J, Wang Y, Yan Q, Wang H, et al
    SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
    Front Immunol. 2025;16:1708324.
    PubMed    
    Abstract available
    
    

55. HAN Y, Peng J, Yan W, Wu Z, et al
    FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
    Hum Mutat. 2025;2025:5947612.
    PubMed    
    Abstract available
    
    

56. CHEN J, Fu Y, Zhang Z, Zhao J, et al
    Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
    Int J Nanomedicine. 2025;20:15235-15275.
    PubMed    
    Abstract available
    
    

57. GONG J, Sun D, Zheng Y, Mao C, et al
    Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
    Food Sci Nutr. 2025;13:e71341.
    PubMed    
    Abstract available
    
    

58. CHEN D, Li Z, Sui Y, Zeng Y, et al
    The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
    iScience. 2025;28:114152.
    PubMed    
    Abstract available
    
    

59. LI Q, Chen QF, Liao NQ
    Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
    PubMed    
    Abstract available
    
    

60. LI M, Liu T, Shi J, Zhou F, et al
    USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
    PubMed    
    
    
    

61. ZHI L, Yuan L
    Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
    Mamm Genome. 2025;37:20.
    PubMed    
    Abstract available
    
    

62. GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
    Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
    World J Urol. 2025;44:59.
    PubMed    
    
    
    

63. D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
    Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
    J Cardiovasc Surg (Torino). 2025;66:532-542.
    PubMed    
    Abstract available
    
    

64. DONG W, Bi J, Liu H, Yan D, et al
    Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
    Mol Cancer. 2025;24:309.
    PubMed    
    
    
    

65. WANG C, Li K, Wan S, Chen S, et al
    TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
    Cell Death Dis. 2025;16:923.
    PubMed    
    Abstract available
    
    

66. YANG H, Liu X, Nie J, Wu S, et al
    USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
    Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
    PubMed    
    Abstract available
    
    

67. ZHAO X, Liu H, Wang C, Guo F, et al
    Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
    Front Genet. 2025;16:1615167.
    PubMed    
    Abstract available
    
    

68. LING Z, He S, Li T, Zhang J, et al
    Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
    Hum Mutat. 2025;2025:5569005.
    PubMed    
    Abstract available
    
    

69. WENG R, Phung TAT, Bell R, Dyrskjot L, et al
    Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70131.
    PubMed    
    Abstract available
    
    

70. MARTEL A, Raue L, Avogbe PH, Raisch J, et al
    Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
    BJUI Compass. 2025;6:e70124.
    PubMed    
    Abstract available
    
    

71. LI C, Lv G, Xiong Z, Wang Z, et al
    Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
    Dose Response. 2025;23:15593258251411761.
    PubMed    
    Abstract available
    
    

72. DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
    Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
    Front Cell Dev Biol. 2025;13:1719978.
    PubMed    
    Abstract available
    
    

73. WANG JM, Xie HY, Zhang FH, Shu X, et al
    Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
    J Hematol Oncol. 2025;18:110.
    PubMed    
    Abstract available
    
    

74. JANENZ J, Leipe A, Urban N, Schaefer M, et al
    Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
    Mol Pharmacol. 2025;108:100096.
    PubMed    
    Abstract available
    
    

75. LI G, Tatarano S, Yoshino H, Saito S, et al
    Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
    Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
    PubMed    
    Abstract available
    
    

76. JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
    Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
    Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
    PubMed    
    Abstract available
    
    

77. JIANG L, Ge W, Feng R, Ji L, et al
    Innovative AI model for bladder cancer diagnosis.
    Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
    PubMed    
    Abstract available
    
    

78. SHI C, Xu J, Chen Q, Gao X, et al
    Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
    Clin Epigenetics. 2025;17:204.
    PubMed    
    Abstract available
    
    

79. XU C, Ying W, He Y, Wu Y, et al
    Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
    Clin Epigenetics. 2025;17:203.
    PubMed    
    Abstract available
    
    

80. JIANG Y, Xu C, He W, Zhang C, et al
    First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
    Int Immunopharmacol. 2026;169:116060.
    PubMed    
    Abstract available
    
    

81. MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
    Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
    ESMO Open. 2025;10:105862.
    PubMed    
    Abstract available
    
    

82. GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
    Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
    Ann Oncol. 2026;37:69-78.
    PubMed    
    Abstract available
    
    

83. CAINI S, Cosma C, Aprea MC, Saieva C, et al
    Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
    Arch Environ Occup Health. 2025;80:303-307.
    PubMed    
    Abstract available
    
    

84. SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
    Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
    Future Oncol. 2025;21:3873-3884.
    PubMed    
    Abstract available
    
    

85. PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
    The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
    Adv Anat Pathol. 2026;33:1-16.
    PubMed    
    Abstract available
    
    

86. WAI R, Sheahen B, Thomas B
    Severe itch from miliaria managed with propantheline: a case report.
    BMJ Support Palliat Care. 2025;16:85-87.
    PubMed    
    Abstract available
    
    

87. HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
    Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
    J Clin Med. 2026;15:338.
    PubMed    
    Abstract available
    
    

88. TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
    Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
    Int J Mol Sci. 2026;27:476.
    PubMed    
    Abstract available
    
    

89. NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
    Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
    Int J Mol Sci. 2025;27:238.
    PubMed    
    Abstract available
    
    

90. JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
    The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
    Diagnostics (Basel). 2025;16:69.
    PubMed    
    Abstract available
    
    

91. JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
    Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;18:136.
    PubMed    
    Abstract available
    
    

92. WU Z, Zeng J, Feng L, Zhu X, et al
    Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
    J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
    PubMed    
    Abstract available
    
    

93. ADMIRE K, Gegick S
    Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
    BMJ Case Rep. 2026;19:e268157.
    PubMed    
    Abstract available
    
    

94. RAGHAVAN D
    Sad But True: Inconsistent Care for Invasive Bladder Cancer.
    JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
    PubMed    
    
    
    

95. YANG FH, Zhang W, Wang R, Mao S, et al
    Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
    Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
    PubMed    
    Abstract available
    
    

96. GATELLIER L, Nakata K
    Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
    Jpn J Clin Oncol. 2026;56:115-116.
    PubMed    
    
    
    

97. ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
    Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
    Ann Med. 2026;58:2612387.
    PubMed    
    
    
    

98. SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
    [Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
    Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
    PubMed    
    Abstract available
    
    

99. REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
    Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
    Radiat Oncol. 2026;21:8.
    PubMed    
    
    
    

100. XU D, Jacob JJ, Wieczorek K, Wang L, et al
     Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
     Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
     PubMed    
     Abstract available
     
     

101. WANG H, Xiong Y, He T, He M, et al
     MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
     BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
     PubMed    
     
     
     

102. WANG J, Lu Q, Jiao P, Jian J, et al
     Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
     Cancer Med. 2026;15:e71477.
     PubMed    
     Abstract available
     
     

103. HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
     Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
     J Cancer Res Clin Oncol. 2026;152:35.
     PubMed    
     Abstract available
     
     

104. JIN Z, Yang W, Peng Y, Ma L, et al
     HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
     FASEB J. 2026;40:e71388.
     PubMed    
     Abstract available
     
     

105. BAI R, Cai L, Jiang M, Wang C, et al
     Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
     Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
     PubMed    
     
     
     

106. DAI P, Chen L, Dong Z, Wang H, et al
     LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
     World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
     PubMed    
     
     
     

107. SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
     Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
     Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
     PubMed    
     Abstract available
     
     

108. SAOULI A, Contieri R, Quhal F, Hurle R, et al
     Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
     Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
     PubMed    
     Abstract available
     
     

109. LI X, Xie J, Song SJ, Ahlquist CSE, et al
     Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
     ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
     PubMed    
     Abstract available
     
     

110. CELLULAR LONGEVITY OMA
     RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
     Oxid Med Cell Longev. 2025;2025:9894089.
     PubMed    
     Abstract available
     
     

111. PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
     Machine-learning-based determination of sex-related bladder cancer biomarkers.
     bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
     PubMed    
     Abstract available
     
     

112. FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
     Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
     Arch Ital Urol Androl. 2025;97:14467.
     PubMed    
     Abstract available
     
     

113. BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
     A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
     Arch Ital Urol Androl. 2025;97:14596.
     PubMed    
     Abstract available
     
     

114. SHI G, Zhou X, Yang F, Wang T, et al
     Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
     Am J Mens Health. 2026;20:15579883251410519.
     PubMed    
     Abstract available
     
     

115. PATTOU M, Robert G, Gouhizoun O, Guena F, et al
     Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
     World J Urol. 2026;44:77.
     PubMed    
     Abstract available
     
     

116. YUAN J, Yu S, Zheng J
     Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
     Chin Clin Oncol. 2025;14:71.
     PubMed    
     Abstract available
     
     

117. FU Q, Yan F, Sun Z, Yao Z, et al
     Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
     Arch Esp Urol. 2025;78:1493-1500.
     PubMed    
     Abstract available
     
     

118. ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
     Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
     Arch Esp Urol. 2025;78:1392-1400.
     PubMed    
     Abstract available
     
     

119. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
     Advances in the management of localized bladder cancers.
     Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
     PubMed    
     Abstract available
     
     

120. ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
     First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
     World J Urol. 2026;44:76.
     PubMed    
     Abstract available
     
     

121. 
     [Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
     Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
     PubMed    
     
     
     

122. HE K, Lin C, Wang H, Wu H, et al
     The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
     Exp Cell Res. 2026;455:114885.
     PubMed    
     Abstract available
     
     

123. MINATO A, Jojima K, Watanabe S, Sugita Y, et al
     Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
     Cancer Diagn Progn. 2026;6:135-143.
     PubMed    
     Abstract available
     
     

124. ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
     Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
     J Robot Surg. 2026;20:151.
     PubMed    
     
     
     

125. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
     High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
     J Biomed Sci. 2026;33:2.
     PubMed    
     Abstract available
     
     

126. MAY M, Wolff I, Brookman-May S, Burger M, et al
     Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
     Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
     PubMed    
     
     
     

127. SAITO M, Kakoi N, Izumi M, Aoki H, et al
     [A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
     Hinyokika Kiyo. 2025;71:425-428.
     PubMed    
     Abstract available
     
     

128. WANG Y, Liu H, Wang T, Yang Y, et al
     GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
     Exp Cell Res. 2026;455:114884.
     PubMed    
     Abstract available
     
     

129. GUO C, Zhou Y, Liu X, Gao K, et al
     Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
     Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
     PubMed    
     Abstract available
     
     

130. LI Y, Zhao B, Gao W, Wu Y, et al
     Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
     Clin Exp Med. 2026;26:62.
     PubMed    
     
     
     

131. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
     Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
     J Cancer Res Clin Oncol. 2026;152:26.
     PubMed    
     
     
     

132. STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
     APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
     Nat Commun. 2025;17:334.
     PubMed    
     Abstract available
     
     

133. LIU P, Zhang L, Zhou Q, Fu Z, et al
     STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
     Chem Biol Interact. 2026;424:111866.
     PubMed    
     Abstract available
     
     

134. YE Y, Chen Q, Huang Z, Huang Q, et al
     Preferred surgical strategies for bladder diverticular carcinoma.
     Sci Rep. 2025;16:917.
     PubMed    
     Abstract available
     
     

135. PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
     Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
     Arch Ital Urol Androl. 2025;97:14167.
     PubMed    
     Abstract available
     
     

136. YU EM, Linville L, Hwang MW, Kim Y, et al
     Harnessing genomic profiling for improved urothelial cancer outcomes.
     Expert Rev Anticancer Ther. 2026;26:93-104.
     PubMed    
     Abstract available
     
     

137. ZHANG T, Zhang X, Qian L, Hu C, et al
     Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
     Biomol Biomed. 2025;26:711-719.
     PubMed    
     Abstract available
     
     

138. DIANA P, Gallioli A, Uleri A, Mas L, et al
     Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
     Actas Urol Esp (Engl Ed). 2026;50:501830.
     PubMed    
     Abstract available
     
     

139. CHENG AV, Bardell J, Sangoi AR
     Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
     Int J Surg Pathol. 2026;34:201-206.
     PubMed    
     Abstract available
     
     

140. HISANAGA E, Sano T, Yokoo H
     Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
     Intern Med. 2026;65:183-186.
     PubMed    
     Abstract available
     
     

141. KAYAR K, Dogan MB, Karabay E
     A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
     Int J Surg Pathol. 2026;34:158-161.
     PubMed    
     Abstract available
     
     

142. KASUKAWA S, Kametaka H, Makino H, Fukada T, et al
     [A Case of Pelvic Abscess Treated with Transperineal Drainage for Lower Gastrointestinal Perforation in Terminal Cancer].
     Gan To Kagaku Ryoho. 2025;52:1189-1191.
     PubMed    
     Abstract available
     
     

143. HATAKEYAMA T, Maeda T, Ide S
     [A Case of Synchronous Primary Cancers of the Rectum and Bladder].
     Gan To Kagaku Ryoho. 2025;52:1129-1130.
     PubMed    
     Abstract available
     
     

144. SALZANO G, Digiacomo A, Dello Stritto G, Orsini A, et al
     Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations.
     Expert Rev Anticancer Ther. 2026 Jan 16. doi: 10.1080/14737140.2026.2619018.
     PubMed    
     Abstract available
     
     

145. CHENG YT, Lu KH, Hong SY, Chen CH, et al
     Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/beta-catenin pathways.
     Part Fibre Toxicol. 2026 Jan 16. doi: 10.1186/s12989-025-00656.
     PubMed    
     Abstract available
     
     

146. YANG J, Li X, Xie H, Guo J, et al
     From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer.
     World J Surg Oncol. 2026 Jan 17. doi: 10.1186/s12957-026-04196.
     PubMed    
     
     
     

147. KHAN JS, Lonergan PE, McLoughlin LC
     Adherence to Bacille Calmette-Guerin protocol in the management of non-muscle invasive bladder cancer at St James's Hospital.
     Ir J Med Sci. 2026 Jan 17. doi: 10.1007/s11845-025-04260.
     PubMed    
     
     
     

148. HAJIME T, Shiota M, Fukuchi G, Mutaguchi J, et al
     Tumor Laterality Predicts Pelvic Lymph Node Metastasis Patterns in Bladder Cancer.
     Ann Surg Oncol. 2026 Jan 16. doi: 10.1245/s10434-026-19088.
     PubMed    
     Abstract available
     
     

149. SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
     Robot-Assisted Radical Cystectomy in the Very Elderly: A Propensity Score-Matched Comparison of Outcomes Between Patients Aged >/= 85 Versus 75-84 Years.
     Geriatr Gerontol Int. 2026;26:e70346.
     PubMed    
     Abstract available
     
     

150. MARAMI S, Tavakoli MH, Pashaki AS, Nikzad S, et al
     Computational analysis of the impact of urine volume on magnetic nanoparticle hyperthermia in the treatment of non-muscle-invasive bladder cancer.
     Eur J Pharm Biopharm. 2026 Jan 14:114992. doi: 10.1016/j.ejpb.2026.114992.
     PubMed    
     Abstract available
     
     

151. DYRSKJOT L, Birkenkamp-Demtroder K, Nordentoft I, Strandgaard T, et al
     ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial.
     Ann Oncol. 2026 Jan 14:S0923-7534(26)00011-6. doi: 10.1016/j.annonc.2025.
     PubMed    
     Abstract available
     
     

152. ZHANG Q, Zhang B, Niu J, Sun S, et al
     POSTN+ cancer-associated fibroblasts promote bladder cancer progression via angiogenesis and immune modulation: an analysis based on single-cell Transcriptomics.
     Integr Biol (Camb). 2026;18:zyag001.
     PubMed    
     Abstract available
     
     

153. KAWAI T, Miki J, Taoka R, Saito R, et al
     Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.
     Jpn J Clin Oncol. 2026 Jan 16:hyaf218. doi: 10.1093.
     PubMed    
     Abstract available
     
     

154. LAERT J, Lupi Manso N, Franca de Santana T, Santos PO, et al
     Pitfalls and Limitations of the Vesical Imaging-Reporting and Data System (VI-RADS): Challenges in the Multiparametric Magnetic Resonance Imaging (mpMRI) Assessment of Bladder Cancer.
     Cureus. 2025;17:e99197.
     PubMed    
     Abstract available
     
     

155. OKA R, Goto Y, Mikami K, Kato H, et al
     Renal Granuloma Distinct From the Renal Pelvis Following Bacillus Calmette-Guerin Treatment for Bladder Cancer: A Case Report.
     IJU Case Rep. 2026;9:e70141.
     PubMed    
     Abstract available
     
     

156. DAI Y, Zhang X, Lin Q, Gu X, et al
     Best evidence summary on gastrointestinal function recovery after radical cystectomy for bladder cancer.
     Asia Pac J Oncol Nurs. 2025;13:100824.
     PubMed    
     Abstract available
     
     

157. REYNARD M, Grobet-Jeandin E, Windisch O, Sebe P, et al
     [Urology. Quality of life and safety : the new promises].
     Rev Med Suisse. 2026;22:79-82.
     PubMed    
     Abstract available
     
     

158. ZHANG J, Zheng L, Yu Z, Chen Y, et al
     Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression.
     Recent Pat Anticancer Drug Discov. 2026.
     PubMed    
     Abstract available
     
     

159. FULORIA NK, Narain K, Biswas A, Gnanam P, et al
     Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker.
     Clin Chim Acta. 2026 Jan 13:120843. doi: 10.1016/j.cca.2026.120843.
     PubMed    
     Abstract available
     
     

160. CONTIERI R, Mollica V, Shariat SF, Pradere B, et al
     Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
     Ann Oncol. 2026 Jan 13:S0923-7534(26)00012-8. doi: 10.1016/j.annonc.2026.
     PubMed    
     
     
     

161. SQUIRES P, Coutinho F, Tepsick JG, Rogiers A, et al
     Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.
     Urol Oncol. 2026;44:110982.
     PubMed    
     Abstract available
     
     

162. ILKI FY, Bulbul E, Topcu YK, Cinar O, et al
     Comparison of intravesical Bacillus Calmette-Guerin and chemohyperthermia with mitomycin C in with high-risk non-muscle-invasive bladder cancer: a critical assesment focusing on the quality of life and adverse events.
     BMC Urol. 2026 Jan 14. doi: 10.1186/s12894-025-02040.
     PubMed    
     
     
     

163. AL-SATTAR H, Ding H, Okoli O, Okoli S, et al
     A multi-modal approach for decision making in bladder cancer.
     Nat Rev Urol. 2026 Jan 14. doi: 10.1038/s41585-025-01122.
     PubMed    
     Abstract available
     
     

164. MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
     Reply to Matthias May, Ingmar Wolff, Sabine Brookman-May, and Maximilian Burger's Letter to the Editor re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Det
     Eur Urol Oncol. 2026 Jan 13:S2588-9311(25)00344.
     PubMed    
     
     
     

165. ZHU M, Liu Y, Jia Y, Ren L, et al
     Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation.
     Cancer Biol Ther. 2026;27:2615418.
     PubMed    
     Abstract available
     
     

166. CAO N, Cheng F
     TSTA3 promotes the malignant progression of bladder cancer by regulating LAMP2 and MAPK signaling pathway-mediated epithelial-mesenchymal transition.
     Genes Genomics. 2026 Jan 14. doi: 10.1007/s13258-025-01724.
     PubMed    
     Abstract available
     
     

167. ARON S, Meagher M, Azari S, Baker B, et al
     Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and Treatment.
     Curr Urol Rep. 2026;27:8.
     PubMed    
     Abstract available
     
     

168. DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
     Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
     J Robot Surg. 2026;20:173.
     PubMed    
     Abstract available
     
     

169. GE T, Liu F, Cai M, Wu J, et al
     Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer.
     Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04404.
     PubMed    
     Abstract available
     
     

170. CHEN J, Liu X, Ren R, Yi R, et al
     Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis.
     Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04440.
     PubMed    
     Abstract available
     
     

171. DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
     Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
     World J Urol. 2026;44:93.
     PubMed    
     Abstract available
     
     

172. WU X, Zhou Y, Chen J, Zhang H, et al
     A high-throughput photothermal aptasensing platform using MnO(2)@CuS nanoprobes for noninvasive detection of bladder cancer cells in simulated liquid biopsy.
     Mikrochim Acta. 2026;193:88.
     PubMed    
     
     
     

173. INUI S, Ito S, Ueda T, Shiraishi T, et al
     Efficacy and safety of cryoablation procedures using mouse models of bladder cancer.
     Sci Rep. 2026 Jan 13. doi: 10.1038/s41598-026-35571.
     PubMed    
     
     
     

174. DADABHOY A, Doshi C, Zahir M, Ladi-Seyedian S, et al
     Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.
     Urol Oncol. 2026;44:110984.
     PubMed    
     Abstract available
     
     

175. MAN X, Zhang X, Dong A, He J, et al
     Isolated Vaginal Recurrence of Urothelial Bladder Cancer on FDG PET/CT.
     Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006294.
     PubMed    
     Abstract available
     
     

176. MJAESS G, Quackels T, Fantoni JC, Tricard T, et al
     Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).
     World J Urol. 2026;44:90.
     PubMed    
     Abstract available
     
     

177. PEREZ-LONDONO A, Kaul S, Fleishman A, Korets R, et al
     Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder.
     World J Urol. 2026;44:91.
     PubMed    
     Abstract available
     
     

178. ZHOU H, Peng S, Ling Z, Cai J, et al
     Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.
     World J Surg Oncol. 2026 Jan 12. doi: 10.1186/s12957-025-04175.
     PubMed    
     
     
     

179. AYDIN ME, Aykac A, Kaya C, Sungur M, et al
     Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer.
     BMC Urol. 2026 Jan 12. doi: 10.1186/s12894-026-02045.
     PubMed    
     Abstract available
     
     

180. REGNIER S, Gabriel PE, Ouzaid I, Moschini M, et al
     Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer.
     World J Urol. 2026;44:84.
     PubMed    
     Abstract available
     
     

181. SUNGUR U, Bitkin A, Eksi M, Polat H, et al
     Machine learning methods for predicting early recurrence in Ta stage bladder cancer and comparison with conventional statistical methods.
     Minerva Urol Nephrol. 2026 Jan 12. doi: 10.23736/S2724-6051.25.06385.
     PubMed    
     Abstract available
     
     

182. ZHANG F, Yang Y, Zhang R, Hu H, et al
     Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer.
     Chin J Cancer Res. 2025;37:1034-1057.
     PubMed    
     Abstract available
     
     

183. 
     Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4 [Retraction].
     Am J Cancer Res. 2025;15:5395.
     PubMed    
     Abstract available
     
     

184. HUANG H, Ye F, Liu T, Hong J, et al
     Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer.
     Cyborg Bionic Syst. 2026;7:0458.
     PubMed    
     Abstract available
     
     

185. DE ALMEIDA MF, Rosa BG, Delechiave D, Annequin LF, et al
     rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model.
     Int J Biol Sci. 2026;22:713-730.
     PubMed    
     Abstract available
     
     

186. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
     Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.
     World J Urol. 2026;44:82.
     PubMed    
     
     
     

187. CHEN L, Jin C, Guo E, Liu F, et al
     The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer.
     J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70232.
     PubMed    
     Abstract available
     
     

188. MUMUNI AN
     Editorial for "The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer".
     J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70238.
     PubMed    
     
     
     

189. CHENG LH, Hsu CW, Yang PM, Liao TY, et al
     Chemotherapy resistance of urinary bladder cancer mediated by a Notch and Wnt co-regulatory module of stemness.
     Stem Cells. 2026 Jan 10:sxag002. doi: 10.1093.
     PubMed    
     Abstract available
     
     

190. SYNESI G, Lewis R, Kilburn L, Bliss J, et al
     Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review.
     Trials. 2026;27:19.
     PubMed    
     Abstract available
     
     

191. KAYRAKLIOGLU N, Zhang L, Cornelia Ding CK, Greenland NY, et al
     Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
     Hum Pathol. 2026;167:106005.
     PubMed    
     Abstract available
     
     

192. FERNANDEZ O, Molina A, Anido-Herranz U, Alvarez C, et al
     Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
     Clin Transl Oncol. 2026;28:254-264.
     PubMed    
     Abstract available
     
     

193. FERNANDEZ RODRIGUEZ P, Castillo Gazquez L, Tomas Alvarez S, Casals Seoane F, et al
     Abdominal BCGitis with hepatosplenic and lymphatic involvement following intravesical therapy: a rare complication.
     Rev Esp Enferm Dig. 2025;117:797-799.
     PubMed    
     Abstract available
     
     

194. PARK I, Lee JL, Yoon S, Shin SJ, et al
     A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03).
     Cancer Res Treat. 2026;58:284-291.
     PubMed    
     Abstract available
     
     

195. MEZEPO G, Khene ZE, Boustani J, Kleinclauss F, et al
     Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
     Eur Urol Oncol. 2026 Jan 22:S2588-9311(25)00343.
     PubMed    
     Abstract available
     
     

196. GABRIEL PE, Xylinas E
     The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management.
     Eur Urol Focus. 2026 Jan 22:S2405-4569(26)00004.
     PubMed    
     Abstract available
     
     

197. REIS LO
     Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG!
     Int Braz J Urol. 2026;52:e20259921.
     PubMed    
     
     
     

198. SUGAWARA D, Hatakeyama K, Konno M, Tozawa T, et al
     Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.
     Abdom Radiol (NY). 2026 Jan 23. doi: 10.1007/s00261-026-05389.
     PubMed    
     Abstract available
     
     

199. ZHAO Q, Gao S, Du Q, Liu Y, et al
     [Expression of Concern] Long non?coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta?catenin signalling pathway.
     Int J Mol Med. 2026;57:66.
     PubMed    
     Abstract available
     
     

200. KUO WT, Pan CC, Liu YW, Chow NH, et al
     Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens.
     Kaohsiung J Med Sci. 2026 Jan 23:e70179. doi: 10.1002/kjm2.70179.
     PubMed    
     Abstract available
     
     

201. LIU L, Liang T, Huang G, Deng D, et al
     Electroacupuncture in Combination with Bevacizumab Hydrogel Provides a Therapeutic Strategy for Bladder Cancer.
     ACS Appl Mater Interfaces. 2026 Jan 22. doi: 10.1021/acsami.6c00404.
     PubMed    
     Abstract available
     
     

202. 
     Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China: Erratum.
     Int J Surg. 2026;112:2201.
     PubMed    
     
     
     

203. DYRSKJOT L
     ctDNA-guided treatment decisions in muscle-invasive bladder cancer.
     Nat Rev Urol. 2026 Jan 22. doi: 10.1038/s41585-026-01125.
     PubMed    
     
     
     

204. HUANG Y, Chen C, Su M, Ye W, et al
     TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer.
     Cancer Lett. 2026;641:218271.
     PubMed    
     Abstract available
     
     

205. DO NT, Nguyen Tung L, Nguyen Cong D, Do MT, et al
     Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis.
     Asian Pac J Cancer Prev. 2026;27:151-156.
     PubMed    
     Abstract available
     
     

206. STROJNY Z, Kanikowska A, Sikora W, Lewandowska M, et al
     First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.
     J Physiol Pharmacol. 2026;76:673-680.
     PubMed    
     Abstract available
     
     

207. NAGUMO Y, Ye X, Shi T, Mathis BJ, et al
     Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering.
     Front Immunol. 2026;16:1629001.
     PubMed    
     Abstract available
     
     

208. NUMATA Y, Ito H, Tatenuma T, Noguchi G, et al
     [A CASE OF ACUTE EXACERBATION OF INTERSTITIAL PNEUMONIA AFTER ROBOT-ASSISTED TOTAL CYSTECTOMY].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:37-40.
     PubMed    
     Abstract available
     
     

209. KURETAKE K, Minato A, Harada S, Fujimoto N, et al
     [CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:10-16.
     PubMed    
     Abstract available
     
     

210. YAMADA R, Hayakawa N, Kikuchi E
     [PERIOPERATIVE INCIDENCE OF VENOUS THROMBOEMBOLISM IN BLADDER CANCER PATIENTS TREATED BY OPEN RADICAL CYSTECTOMY].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:1-9.
     PubMed    
     Abstract available
     
     

211. HUSSEIN AA, Klugman Y, Carlson J, Bhat TA, et al
     Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.
     Urol Oncol. 2026;44:110978.
     PubMed    
     Abstract available
     
     

212. CALOUDAS AB, Haltom TM, Taylor JM
     "It's Killed My Sex Life": Veteran Bladder Cancer Survivors' Perspectives on Sexual Problems and Intimacy.
     Arch Sex Behav. 2026 Jan 21. doi: 10.1007/s10508-025-03364.
     PubMed    
     Abstract available
     
     

213. SONG S MSC, Yang W MSc, Gao C MD
     Comment on "The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: a meta-analysis and systematic review".
     Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004892.
     PubMed    
     
     
     

214. LI M, Liu X, Xue Y, Lu Y, et al
     Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.
     Front Oncol. 2026;15:1716324.
     PubMed    
     Abstract available
     
     

215. YAN B, Hu W, Li Y, Feng T, et al
     Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.
     Front Oncol. 2026;15:1715762.
     PubMed    
     Abstract available
     
     

216. SONG F, Su S, Zhang X, Cao Y, et al
     Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
     Front Oncol. 2026;15:1710047.
     PubMed    
     Abstract available
     
     

217. REDDY N, Lau K, Naman J, Lu K, et al
     Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.
     Oncoimmunology. 2026;15:2611458.
     PubMed    
     Abstract available
     
     

218. FAN D, Meng R, Han Y, Zhai Z, et al
     Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates.
     Medicine (Baltimore). 2026;105:e47176.
     PubMed    
     Abstract available
     
     

219. CAI J, Jiao C, Xu Y, Zhang F, et al
     Polarity protein Par3 deficiency promotes metastasis of bladder cancer via interaction of Ppp1r12c.
     Biol Direct. 2026 Jan 20. doi: 10.1186/s13062-026-00727.
     PubMed    
     
     
     

220. LI Y, Zhou Z, Liu J, Cheng Z, et al
     En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
     World J Surg Oncol. 2026 Jan 20. doi: 10.1186/s12957-025-04172.
     PubMed    
     
     
     

221. JIANG M, Chen S, Ma H, Shi Y, et al
     Intratumoral and Peritumoral Fat CT?Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.
     Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-18981.
     PubMed    
     Abstract available
     
     

222. HE W, Wen Y, Qin H
     LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.
     Urol Oncol. 2026;44:110980.
     PubMed    
     Abstract available
     
     

223. SHANG LL, Hu TL, Xiong S, Xu S, et al
     Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer.
     Eur J Med Chem. 2026;306:118581.
     PubMed    
     Abstract available
     
     

224. STUART J, Zhuleku E, Mevius A, Squires P, et al
     Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.
     Oncol Ther. 2026 Jan 20. doi: 10.1007/s40487-025-00413.
     PubMed    
     Abstract available
     
     

225. HAYAKAWA N, Kikuchi E
     [Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma].
     Gan To Kagaku Ryoho. 2026;53:21-24.
     PubMed    
     Abstract available
     
     

226. KITA Y
     [Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer].
     Gan To Kagaku Ryoho. 2026;53:16-20.
     PubMed    
     Abstract available
     
     

227. SHIGEHISA R, Fukata S, Inoue K
     [Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].
     Gan To Kagaku Ryoho. 2026;53:10-15.
     PubMed    
     Abstract available
     
     

228. KAWAHARA T
     [Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].
     Gan To Kagaku Ryoho. 2026;53:7-9.
     PubMed    
     Abstract available
     
     

229. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
     Author Correction: Advances in the management of localized bladder cancers.
     Nat Rev Clin Oncol. 2026 Jan 19. doi: 10.1038/s41571-026-01121.
     PubMed    
     
     
     

230. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
     Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
     World J Urol. 2026;44:111.
     PubMed    
     Abstract available
     
     

231. ZHAO Z, Zhao Z, Bu X, Wang M, et al
     Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.
     Abdom Radiol (NY). 2026 Jan 19. doi: 10.1007/s00261-025-05365.
     PubMed    
     Abstract available
     
     

232. EL MJABBER R, Alami R, Aouzah F, Bezzari W, et al
     Integrated Boost vs. Sequential Scheme in Volumetric Modulated Arc Therapy (VMAT) for Trimodal Bladder Cancer Therapy: A Comparative Study.
     Cureus. 2025;17:e99438.
     PubMed    
     Abstract available
     
     

233. KAUFMANN E, Aeppli S, Affentranger A, Arnold N, et al
     Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
     Bladder Cancer. 2026;12:23523735251410823.
     PubMed    
     Abstract available
     
     

234. WU J, Jin S, Bai Q, Wang H, et al
     Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.
     MedComm (2020). 2026;7:e70592.
     PubMed    
     Abstract available
     
     

235. YAMANAKA R, Miura K, Yamasaki N, Ogata S, et al
     Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan.
     Hypertens Res. 2026 Jan 19. doi: 10.1038/s41440-025-02535.
     PubMed    
     Abstract available
     
     

236. LU L, Cheng H, Liu S, Tao Y, et al
     TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.
     Mol Cancer Ther. 2026 Jan 19. doi: 10.1158/1535-7163.MCT-25-0507.
     PubMed    
     Abstract available
     
     

237. XU T, Wang K, Chen Y, Yu Y, et al
     Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
     Int Immunopharmacol. 2026;172:116186.
     PubMed    
     Abstract available
     
     

238. RICHTERS A, Franken MD, Meijer RP, van der Heijden AG, et al
     Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study.
     Cancer Treat Res Commun. 2026;46:101099.
     PubMed    
     Abstract available
     
     

239. MOHAMED T, Bani Irshid BA, Elhashamy H, Deameh MG, et al
     Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
     Langenbecks Arch Surg. 2026;411:58.
     PubMed    
     Abstract available
     
     

240. RICCIARDI G, Tralongo P, Pierconti F, Zuccala V, et al
     Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.
     Clin Genitourin Cancer. 2026;24:102478.
     PubMed    
     Abstract available
     
     

241. KURIAN M, Mamtani R, Elghawy O, Nimgaonkar V, et al
     Real-World Enfortumab Vedotin +/- Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma.
     Clin Genitourin Cancer. 2026;24:102474.
     PubMed    
     Abstract available
     
     

242. WENG C, Deng H, Yang Z, Zeng X, et al
     Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.
     J Transl Med. 2025;24:85.
     PubMed    
     Abstract available
     
     

243. CARVALHO D, Pinto S, Sarmento B
     Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.
     Acta Biomater. 2026;210:296-313.
     PubMed    
     Abstract available
     
     

244. REVERDY T, Izarn F, Allignet B, Roubaud G, et al
     Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
     Clin Genitourin Cancer. 2026;24:102465.
     PubMed    
     Abstract available
     
     

245. COCA MEMBRIBES S, Szabados B, Powles T
     Towards biomarker-driven therapies for urothelial carcinoma.
     Nat Rev Clin Oncol. 2026;23:92-106.
     PubMed    
     Abstract available
     
     

246. LITT HK, Mamtani R, Chow RD
     Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
     Urol Oncol. 2026;44:118.
     PubMed    
     Abstract available
     
     

247. DOGRA S, Lee J, Siriruchatanon M, Gu Z, et al
     Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.
     Acad Radiol. 2026;33:472-481.
     PubMed    
     Abstract available
     
     

248. CHEVILLE JC, Orme JJ, Gupta S, Lucien-Matteoni F, et al
     Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes.
     Mod Pathol. 2026;39:100928.
     PubMed    
     Abstract available
     
     

249. MAREI A, Hohls M, Touloumtzidis A, Katoh M, et al
     Metastasis of an urothelial carcinoma as rare cause of an AV-graft dysfunction in a transgender patient.
     J Vasc Access. 2026;27:326-331.
     PubMed    
     Abstract available
     
     

250. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
     Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
     BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
     PubMed    
     Abstract available
     
     

251. MENNES J, Akand M, Benijts R, Baekelandt L, et al
     Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
     BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
     PubMed    
     Abstract available
     
     

252. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
     Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
     BJU Int. 2026;137:323-331.
     PubMed    
     Abstract available
     
     

253. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
     Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
     BJU Int. 2026;137:270-281.
     PubMed    
     Abstract available
     
     

254. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
     Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
     BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
     PubMed    
     Abstract available
     
     

255. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
     Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
     BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
     PubMed    
     Abstract available
     
     

256. CHEVRIER S, Richard C, Adotevi O, Ayyoub M, et al
     Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.
     Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-2306.
     PubMed    
     Abstract available
     
     

257. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
     Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
     Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
     PubMed    
     Abstract available
     
     

258. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
     RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
     Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
     PubMed    
     Abstract available
     
     

259. FILHO AM, Briganti A, Jemal A, Bray F, et al
     Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
     Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
     PubMed    
     Abstract available
     
     

260. HERR H
     Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
     Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
     PubMed    
     
     
     

261. ROVIELLO G, Vascotto IA, Antonuzzo L
     Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
     Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

262. KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
     Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
     Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

263. GARMAN TS, Kates MR
     Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
     Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

264. PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
     Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
     Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

265. NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
     Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
     Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
     PubMed    
     Abstract available
     
     

266. NIEDERSUESS-BEKE D, Mayrhofer K, Krauter J, Franke J, et al
     Enfortumab vedotin plus pembrolizumab in treatment-naive metastatic urothelial carcinoma patients: An Austrian real-world analysis.
     Int J Cancer. 2026;158:1654-1665.
     PubMed    
     Abstract available
     
     

267. DU J, Shen H, Zeng T, Liu W, et al
     Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
     Int J Oncol. 2026;68:28.
     PubMed    
     Abstract available
     
     

268. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
     Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
     Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
     PubMed    
     Abstract available
     
     

269. FIORENTINO V
     Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
     Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
     PubMed    
     
     
     

270. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
     Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
     Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
     PubMed    
     Abstract available
     
     

271. IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
     Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
     Int J Urol. 2026;33:e70341.
     PubMed    
     Abstract available
     
     

272. HIRATA H
     Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
     Int J Urol. 2026;33:e70343.
     PubMed    
     
     
     

273. FUJITA N
     Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
     Int J Urol. 2026;33:e70358.
     PubMed    
     
     
     

274. SOMA T, Tanaka H, Nakamura Y, Numao N, et al
     Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
     Int J Urol. 2026;33:e70329.
     PubMed    
     Abstract available
     
     

275. ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
     Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
     Int J Urol. 2026;33:e70330.
     PubMed    
     Abstract available
     
     

276. CHAI Y, Zhou Y, Peng H, Jiang Y, et al
     Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
     Int Urol Nephrol. 2026 Jan 11. doi: 10.1007/s11255-026-05008.
     PubMed    
     Abstract available
     
     

277. PAN XW, Li L, Huang Y, Huang H, et al
     [Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
     Oncol Rep. 2026;55:51.
     PubMed    
     Abstract available
     
     

278. TJIAMAN MP, Zaidan MZ, Ausath ZF, Putri AT, et al
     Quality of Life and Postoperative Complications of Single- or Bilateral-stoma Cutaneous Ureterostomy Compared to Ileal Conduit After Radical Cystectomy: A Systematic Review and Meta-analysis.
     Urology. 2026;207:287-292.
     PubMed    
     Abstract available
     
     

279. HEARD JR, Pagano I, Rosser C, Tan WS, et al
     Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
     Urology. 2026;207:178-183.
     PubMed    
     Abstract available
     
     

280. YANG IN, Liang CA, Wu CC, Xu QS, et al
     Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
     BMC Cancer. 2025;25:1900.
     PubMed    
     Abstract available
     
     

281. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
     Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
     BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
     PubMed    
     Abstract available
     
     

282. DARJI S, Qu F, Henager M, Prasad A, et al
     Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
     Proc Natl Acad Sci U S A. 2026;123:e2502486122.
     PubMed    
     Abstract available